City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt Disease

• City Therapeutics dosed the first participant in a Phase 1 trial of CITY-RBP4 for Stargardt disease, advancing its second program into clinical testing.
• Initial results are expected in mid-2027; the study will evaluate safety, tolerability and biological activity in healthy volunteers and patients.
• The RNAi candidate aims to reduce vitamin A delivery to the eye, potentially slowing retinal damage and vision loss.
• Stargardt disease has no approved treatments; a planned extension study will assess long-term safety and preliminary efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. City Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874004) on November 10, 2026, and is solely responsible for the information contained therein.